Biomedica’s AI-Powered Osteoporosis and Sarcopenia Analysis System Joins Dalin Tzu Chi Hospital

In response to the challenges of an aging population and growing concerns over skeletal health, Biomedica has announced that its AI-powered Bone Density Imaging Software and Qcheck Sarcopenia Analysis Solution have been officially adopted by Dalin Tzu Chi Hospital. This collaboration not only marks a significant milestone in the real-world application of medical AI technology but also strengthens the hospital's capabilities in preventive care for the elderly, laying a solid foundation for smart health management. As a key regional medical center in the Yunlin–Chiayi–Tainan area, Dalin Tzu Chi Hospital has long been committed to clinical care and health education for osteoporosis and sarcopenia in the elderly. With the integration of Biomedica’s advanced AI diagnostic systems, the hospital has significantly improved its screening efficiency and diagnostic accuracy while streamlining clinical workflows. By harnessing AI, healthcare resources can be more rapidly extended to community and primary care settings, promoting early disease detection and timely intervention—realizing the core principles of preventive medicine within the long-term care system.

Upholding its core philosophy of “Simple and Precise,” Biomedica’s bone density imaging software requires only standard X-ray equipment combined with AI computation to automatically generate bone density reports in just six seconds. Its proprietary X1AI-Osteo AI analysis module can swiftly identify osteoporosis risk and assist physicians in making timely clinical decisions. According to a study published by the Taiwan Osteoporosis Association, the module’s results show a high correlation with the gold standard DXA (R=0.996), proving its high accuracy and clinical feasibility. The system has earned wide recognition from orthopedic and internal medicine physicians.

Beyond real-world deployments, Biomedica actively engages with the medical community. At the 87th Spring Joint Conference of the Taiwan Orthopaedic Association (TOA) this year, the company showcased its AIXA AI-Assisted Analysis Solution for Osteoporosis, Sarcopenia, and Fracture Risk, demonstrating its clinical performance and application benefits to specialists in orthopedics, endocrinology, and radiology. Biomedica’s AI osteoporosis system has already expanded to 11 countries across the Asia-Pacific, with adoption in over 150 medical institutions, accelerating the clinical implementation of smart medical technologies and helping healthcare systems advance more precise and efficient approaches to osteoporosis prevention and health management.